Revolution Medicines, Inc. (RVMD)
211.58
+2.12
(+1.01%)
USD |
NASDAQ |
Aug 24, 16:00
211.40
-0.18
(-0.09%)
After-Hours: 19:19
Revolution Medicines Debt to Equity Ratio : 0.4568 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.4568 |
| March 31, 2026 | 0.2915 |
| December 31, 2025 | 0.2618 |
| September 30, 2025 | 0.0992 |
| June 30, 2025 | 0.0712 |
| March 31, 2025 | 0.0646 |
| December 31, 2024 | 0.06 |
| September 30, 2024 | 0.0554 |
| June 30, 2024 | 0.054 |
| March 31, 2024 | 0.051 |
| December 31, 2023 | 0.0482 |
| September 30, 2023 | 0.075 |
| June 30, 2023 | 0.068 |
| March 31, 2023 | 0.0668 |
| December 31, 2022 | 0.0937 |
| September 30, 2022 | 0.0957 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.1302 |
| March 31, 2022 | 0.1196 |
| December 31, 2021 | 0.1106 |
| September 30, 2021 | 0.0498 |
| June 30, 2021 | 0.0474 |
| March 31, 2021 | 0.0443 |
| December 31, 2020 | 0.0689 |
| September 30, 2020 | 0.0661 |
| June 30, 2020 | 0.0945 |
| March 31, 2020 | 0.0281 |
| December 31, 2019 | 0.0011 |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.0015 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Tango Therapeutics, Inc. | 0.0312 |
| Erasca, Inc. | 0.1236 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Intellia Therapeutics, Inc. | 0.1009 |
| Beam Therapeutics, Inc. | 0.2317 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 4.323B |
| Total Liabilities (Quarterly) | 1.717B |
| Shareholders Equity (Quarterly) | 2.606B |
| Current Ratio | 11.38 |
| Net Debt Paydown Yield | -0.53% |